{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:51:44Z","timestamp":1792803104844,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["101-2313-B-003-002-MY3"],"award-info":[{"award-number":["101-2313-B-003-002-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006397","name":"National Taiwan Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Nutritional Biochemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jnutbio.2019.108227","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T10:55:52Z","timestamp":1567248952000},"page":"108227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib"],"prefix":"10.1016","volume":"74","author":[{"given":"Chi-Shiuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-An","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Hsuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ren","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ying F.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jnutbio.2019.108227_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13304-016-0359-y","article-title":"Worldwide burden of colorectal cancer: a review","volume":"68","author":"Favoriti","year":"2016","journal-title":"Updates Surg"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0010","first-page":"5171","article-title":"KRAS mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/CMAR.S52217","article-title":"Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management","volume":"6","author":"Khan","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0020","first-page":"2949","article-title":"Molecular profiling in the treatment of colorectal cancer: focus on regorafenib","volume":"8","author":"Yan","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(12)62006-6","article-title":"Evaluation of regorafenib in colorectal cancer and GIST","volume":"381","author":"Waddell","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.gendis.2014.10.002","article-title":"Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer","volume":"2","author":"Knickelbein","year":"2015","journal-title":"Genes Dis"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0040","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/jcp.25890","article-title":"Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer","volume":"233","author":"Bahrami","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0045","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the 'undruggable' cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","article-title":"Synthetic lethality: general principles, utility and detection using genetic screens in human cells","volume":"585","author":"Nijman","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13062-015-0086-1","article-title":"Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer","volume":"10","author":"Srihari","year":"2015","journal-title":"Biol Direct"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0065","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0070","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.21873\/anticanres.11147","article-title":"Molecular mechanisms of anti-metastatic activity of curcumin","volume":"36","author":"Deng","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0075","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bph.13621","article-title":"Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases","volume":"174","author":"Kunnumakkara","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1055-9965.120.14.1","article-title":"Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences","volume":"14","author":"Garcea","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010263","article-title":"Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application","volume":"19","author":"Seca","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0090","doi-asserted-by":"crossref","first-page":"9951","DOI":"10.1073\/pnas.86.24.9951","article-title":"Cytochemical observation of regulated bacterial beta-galactosidase gene expression in mammalian cells","volume":"86","author":"Liu","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0095","first-page":"983","article-title":"Control of ha-ras-mediated mammalian cell transformation by Escherichia coli regulatory elements","volume":"52","author":"Liu","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0100","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1074\/jbc.271.14.7992","article-title":"Oncogenic Neu\/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation","volume":"271","author":"Galang","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0105","first-page":"2913","article-title":"Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites","volume":"9","author":"Galang","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0110","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/carcin\/bgi133","article-title":"Justicidin A decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cells","volume":"26","author":"Lee","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejmech.2017.03.034","article-title":"Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction","volume":"132","author":"Su","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0120","first-page":"217","article-title":"Two new formulae for evaluating the effectiveness of drug combinations and the revision of Burgi's and Jin's modified Burgi's formulae","volume":"5","author":"Zhou","year":"1984","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0125","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2007-07-099325","article-title":"Aurora kinase inhibitory VX-680 increases Bax\/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia","volume":"111","author":"Huang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.bjc.6601131","article-title":"Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin\/5-fluorouracil","volume":"89","author":"Magne","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0135","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.celrep.2014.07.033","article-title":"RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells","volume":"8","author":"Lamba","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0140","first-page":"145","article-title":"Approaches to identifying synthetic lethal interactions in cancer","volume":"88","author":"Thompson","year":"2015","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0145","doi-asserted-by":"crossref","first-page":"12217","DOI":"10.1073\/pnas.1508573112","article-title":"Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival","volume":"112","author":"Megchelenbrink","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0150","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJMra1407390","article-title":"Applying synthetic lethality for the selective targeting of cancer","volume":"371","author":"McLornan","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2012.11.007","article-title":"Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models","volume":"23","author":"Corcoran","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1078-0432.CCR-15-0829","article-title":"Sensitivity of KRAS-mutant colorectal cancers to combination therapy that cotargets MEK and CDK4\/6","volume":"22","author":"Ziemke","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0165","doi-asserted-by":"crossref","first-page":"22976","DOI":"10.3390\/ijms160922976","article-title":"Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers","volume":"16","author":"Temraz","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/excr.1999.4689","article-title":"Isotype-specific functions of Raf kinases","volume":"253","author":"Hagemann","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0175","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0180","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1038\/srep04694","article-title":"JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy","volume":"4","author":"Sui","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0185","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jnutbio.2014.01.003","article-title":"Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs","volume":"25","author":"Ke","year":"2014","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0190","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12967-014-0216-z","article-title":"AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment","volume":"12","author":"Caputo","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fphar.2015.00120","article-title":"Combined inhibition of MEK and Aurora A kinase in KRAS\/PIK3CA double-mutant colorectal cancer models","volume":"6","author":"Davis","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0200","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1158\/1535-7163.MCT-16-0066","article-title":"Pharmacological profile of BI 847325, an orally bioavailable, ATP-competitive inhibitor of MEK and Aurora kinases","volume":"15","author":"Sini","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0205","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/09637486.2013.871694","article-title":"Curcumin-enhanced chemosensitivity of FDA-approved platinum (II)-based anti-cancer drugs involves downregulation of nuclear endonuclease G and NF-kappaB as well as induction of apoptosis and G2\/M arrest","volume":"65","author":"Wang","year":"2014","journal-title":"Int J Food Sci Nutr"},{"key":"10.1016\/j.jnutbio.2019.108227_bb0210","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/0008-5472.CAN-13-2966","article-title":"The four faces of autophagy: implications for cancer therapy","volume":"74","author":"Gewirtz","year":"2014","journal-title":"Cancer Res"}],"container-title":["The Journal of Nutritional Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955286318312440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955286318312440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:20:35Z","timestamp":1778779235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955286318312440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"alternative-id":["S0955286318312440"],"URL":"https:\/\/doi.org\/10.1016\/j.jnutbio.2019.108227","relation":{},"ISSN":["0955-2863"],"issn-type":[{"value":"0955-2863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib","name":"articletitle","label":"Article Title"},{"value":"The Journal of Nutritional Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnutbio.2019.108227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108227"}}